Get latest articles and stories on Business at LatestLY. Mumbai (Maharashtra) [India], November 27: In a country with over 1.4 million[i] cases reported annually, with most being reported at later stages, adaptive radiotherapy (ART) is a…
Adult patients with an aggressive form of leukemia will be able to receive a breakthrough immunotherapy, which was invented by UCL researchers, on the NHS within weeks following approval for use by the National Institute for Health and…
Cancer patients in Abuja have received a significant boost after the NNPC/Renaissance Joint Venture contributed $300,000 to the National Hospital, Abuja, ensuring the continued operation of its advanced cancer treatment equipment. The…
The NNPC/Renaissance JV donates $300,000 to sustain advanced cancer treatment in Nigeria at the National Hospital, ensuring uninterrupted patient care.
Some of the benefits of the intervention to include: treatment of over 2,000 patients, reduction of treatment cost by 80%, reduction of therapy session time from 12 minutes to 2 minutes, subsidised care for indigent patients, with 712 of…
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence - a condition associated with significantly…
For some patients with the most common type of lung cancer, known as lung adenocarcinoma, there's new hope. In a new study published in Cell Reports, Mayo Clinic researchers have found several previously unknown genetic and cellular…
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence—a condition associated with significantly worse…
A new immunotherapy for a severe form of blood cancer will soon be available on the NHS, offering new hope to adults whose disease has returned or stopped responding to conventional treatment.
A study of 6,800 colon cancer patients found those who took Ozempic or Mounjaro were more likely to survive the disease. It may boil down to inflammation.
The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The Lancet Oncology outlining how its…
Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by…
The SISAQOL-IMI consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has published a paper in The Lancet Oncology outlining how its recommendations for patient-reported…